Post on 31-Aug-2020
Firs
t N
ame
Mid
dle
Initi
al
Last
Nam
e
❏ P
hysi
cian
❏
Fel
low
❏
PA
-C
❏
Nur
se
❏
NP
❏
PhD
❏
Pha
rmac
ist
❏
Indu
stry
Cre
dent
ials
Mai
ling
Addr
ess
City
Prov
/St
ate
Cou
ntry
Post
al/
Zip
Cod
e
E-m
ail (
Your
con
firm
atio
n w
ill b
e se
nt v
ia e
-mai
l)
Phon
e
Fax
Spec
ialty
Birt
h D
ate
(MM
/D
D/
YYYY
)
Inst
itute
/O
rgan
izat
ion
Paym
ent
can
be m
ade
by: ❏
Che
ck
❏
VIS
A
❏
Mas
terC
ard
❏
Dis
cove
r
❏ A
mer
ican
Exp
ress
Cha
rge
Amou
nt
Car
d N
umbe
r
Expi
ratio
n D
ate
Nam
e as
It A
ppea
rs o
n C
redi
t C
ard
Se
curit
y C
ode
Billi
ng A
ddre
ss o
f Car
d (if
diff
eren
t fr
om a
bove
; zip
cod
e re
quire
d)
Sign
atur
e
9th
Annu
al I
nter
natio
nal S
ympo
sium
on
Ovar
ian
Canc
er a
nd G
ynec
olog
ic M
alig
nanc
ies®
RE
GIS
TR
AT
ION
Prac
tice
Set
ting
:
❏ A
cade
mic
med
ical
cen
ter/
univ
ersi
ty
❏ L
abor
ator
y/ba
sic
rese
arch
❏
Pha
rmac
y
❏ C
omm
unity
hos
pita
l-bas
ed p
ract
ice
❏ G
over
nmen
t ag
ency
❏ C
omm
unity
off
ice-
base
d pr
actic
e ❏
Pha
rmac
eutic
al/
biot
echn
olog
y co
mpa
ny
❏ In
tra
inin
g (fe
llow
, res
iden
t, st
uden
t)
❏ O
ther
Wha
t is
you
r pr
inci
pal a
ctiv
ity?
❏ P
atie
nt c
are
❏
Clin
ical
res
earc
h
❏ T
each
ing/
trai
ning
❏
Adm
inis
trat
ive
❏
Oth
er
Pref
erre
d ed
ucat
iona
l for
mat
s:
❏ L
ive
❏
Onl
ine
❏
Prin
t
Pref
erre
d m
etho
ds o
f com
mun
icat
ion:
❏ P
hone
❏
Mai
l ❏
E-m
ail
Wou
ld y
ou li
ke t
o pa
rtic
ipat
e in
CM
E su
rvey
s? ❏
Yes
❏ N
o
How
man
y ca
ncer
pat
ient
s do
you
tre
at e
ach
mon
th?
Year
s pr
actic
ing
med
icin
e
Plea
se c
heck
the
app
ropr
iate
cat
egor
y:
Adv
ance
On-
Site
❏ P
hysi
cian
s$1
29$1
79
❏ N
urse
s, P
As, o
ther
$79
$129
❏ F
ello
ws
$79
$129
❏ In
dust
ry**
$259
$299
*FEL
LOW
S re
gist
ratio
n m
ust
be a
ccom
pani
ed b
y a
lett
er f
rom
you
r di
rect
or/
chai
r st
atin
g cu
rren
t fe
llow
ship
for
disc
ount
. C
anno
t be
com
bine
d w
ith o
ther
dis
coun
ts/
coup
on c
odes
. **
IND
UST
RY is
def
ined
by
PER
as a
ny p
erso
n em
ploy
ed b
y a
for-
prof
it or
gani
zatio
n, in
clud
ing
biot
ech,
fina
ncia
l, an
d ph
arm
aceu
tical
.
A c
ance
llatio
n fe
e of
25%
will
be
asse
ssed
on
refu
nds
requ
este
d pr
ior
to S
epte
mbe
r 13
, 201
3, a
nd a
50%
fee
on r
efun
ds r
eque
sted
on
Sep
tem
ber
14, 2
013,
thr
ough
Sep
tem
ber
27, 2
013.
No
refu
nds
will
be
mad
e af
ter
Sept
embe
r 28
, 201
3. T
here
is n
o ch
arge
for
subs
titut
ion.
Sub
stit
utio
ns c
an o
nly
be a
pplie
d to
the
sa
me
conf
eren
ce a
nd o
nly
two
subs
titu
tion
s w
ill b
e ho
nore
d. I
n th
e ev
ent
of a
mee
ting
canc
ella
tion,
ful
l ref
unds
will
be
proc
esse
d w
ithin
30
days
of
the
canc
ella
tion
date
.
For
regi
stra
tion
assi
stan
ce, p
leas
e e-
mai
l inf
o@go
tope
r.com
, cal
l (88
8) 9
49-0
045,
or
visi
t go
tope
r.com
.
Regi
stra
tion
fees
incl
ude
cont
inen
tal b
reak
fast
, bre
aks,
and
lunc
h.
Plea
se c
ompl
ete
the
form
to
the
left
, and
mai
l it
with
you
r pa
ymen
t (c
heck
s an
d cr
edit
card
s ar
e ac
cept
ed) t
o th
e ad
dres
s be
low
. To
regi
ster
by
phon
e or
fax,
ple
ase
call
(888
) 949
-004
5 or
fax
(609
) 257
-070
5 (c
redi
t ca
rds
only
).
Plea
se m
ake
chec
ks p
ayab
le t
o Ph
ysic
ians
’ Edu
catio
n Re
sour
ce®,
LLC
- IO
G13
.
All p
aym
ents
mus
t be
mad
e by
a d
raft
on
a U
nite
d St
ates
ban
k.
Phys
icia
ns’ E
duca
tion
Reso
urce
®, L
LC, f
ully
com
plie
s w
ith th
e le
gal r
equi
rem
ents
of t
he A
DA
and
the
rule
s an
d re
gula
tions
ther
eof.
If an
y pa
rtic
ipan
t in
this
edu
catio
nal a
ctiv
ity is
in n
eed
of
acco
mm
odat
ions
, ple
ase
notif
y us
in o
rder
to r
ecei
ve s
ervi
ce. P
leas
e ca
ll (8
88) 9
49-0
045.
Phys
icia
ns’ E
duca
tion
Reso
urce
®, L
LC66
6 Pl
ains
boro
Rd,
Ste
356
Plai
nsbo
ro, N
J 085
36
Thre
e w
ays
to r
egis
ter:
1) G
o to
our
web
site
at
goto
per.c
om
2) F
ill o
ut t
he r
egis
trat
ion
form
and
fa
x it
to (
609)
257
-070
5
(cre
dit
card
s on
ly)
3) C
all (
888)
949
-004
5
✁
Phys
icia
ns’ E
duca
tion
Reso
urce
®, L
LC66
6 Pl
ains
boro
Rd,
Ste
356
Plai
nsbo
ro, N
J 085
36
Cou
rse
Dire
ctor
s
Jam
es T
ate
Thig
pen
, MD
Pr
ofes
sor
of M
edic
ine
Dire
ctor
, Div
isio
n of
Med
ical
Onc
olog
yU
nive
rsity
of M
issi
ssip
pi S
choo
l of M
edic
ine
Jack
son,
Mis
siss
ippi
Mau
rie
Mar
kman
, MD
Seni
or V
ice
Pres
iden
t of C
linic
al A
ffai
rs &
Nat
iona
l Dire
ctor
, Med
ical
Onc
olog
yC
ance
r Tr
eatm
ent C
ente
rs o
f Am
eric
aPh
ilade
lphi
a, P
enns
ylva
nia
Mic
hael
J. B
irre
r, M
D, P
hDPr
ofes
sor,
Dep
artm
ent o
f Med
icin
eH
arva
rd M
edic
al S
choo
lD
irect
or o
f Gyn
ecol
ogic
Med
ical
Onc
olog
yM
assa
chus
etts
Gen
eral
Hos
pita
lBo
ston
, Mas
sach
uset
tsSa
turd
ay,
Oct
ob
er 5
, 20
13Lo
ews
Phila
del
phi
a H
otel
Phila
del
phi
a, P
A
Satu
rda
y, O
cto
ber
5, 2
013
Loew
s Ph
ilad
elp
hia
Hot
elPh
ilad
elp
hia
, PA
Ova
rian
Can
cer
AN
D G
YN
EC
OLO
GIC
MA
LIG
NA
NC
IES
®
INT
ER
NA
TIO
NA
L S
YM
PO
SIU
M O
N9t
h A
nnua
l
For
mor
e in
form
atio
n an
d re
gist
ratio
n, v
isit
us a
t
Ova
rian
Can
cer
AN
D G
YN
EC
OLO
GIC
MA
LIG
NA
NC
IES
®
INT
ER
NA
TIO
NA
L S
YM
PO
SIU
M O
N9t
h A
nnua
l
Act
No
w!
Regi
ster
by
Sept
embe
r 15t
h an
d sa
ve $
25!
Use
cod
e: O
13B
RO
**D
isco
unt a
vaila
ble
for p
hysi
cian
s on
ly.
For
mor
e in
form
atio
n an
d re
gist
ratio
n, v
isit
us a
t
Saturday, October 5, 2013Loews Philadelphia Hotel • Philadelphia, PA
COURSE DIRECTORS FACULTY
RECOMMENDED ACCOMMODATIONS
Loews Philadelphia Hotel1200 Market StreetPhiladelphia, PA 19107Information: (215) 627-1200Reservations: (888) 575-6397
A limited block of rooms has been set aside at Loews Philadelphia Hotel at a deluxe room rate of $179 plus applicable state and local taxes. Rates and rooms are subject to availability at the time of the reservation.
To make a reservation, call (888) 575-6397. The deadline for making your hotel reservations is September 20, 2013. After that date, or in the event that the room block becomes full prior to the deadline, rooms are subject to availability, and the room rates may increase. When booking, please mention PER Ovarian Cancer Symposium to receive the discounted group rate.
TRAVEL ARRANGEMENTSPER® recommends that you make your reservations early to get the best seat options and lowest airfare available. Philadelphia International Airport (PHL) is 9.2 miles from the hotel. Our travel partner, TraveLink, is available to assist in making travel arrangements. Please call (866) 301-3011 and ask for Peter Carson (ext. 2034) or Darrell Roberts (ext. 5193). You can also e-mail your request to Peter Carson at pcarson@trvlnk.com.
Register today and save!
SATURDAY, OCTOBER 5TH7:00 am Registration and Continental Breakfast
Morning Session
8:00 am Welcome and Framing of the Day’s EventsJames Tate Thigpen, MD
8:10 am Expert Debate #1: Patients with newly diagnosed Stage III ovarian carcinoma should undergo a laparotomy with staging and an aggressive attempt at bulk reduction prior to receiving chemotherapy.Pro: Mark A. Morgan, MD, FACOG, FACS Con: Robert Allen Burger, MD, FACOG, FACS
8:40 am Expert Debate #2: The treatment of choice for patients with newly diagnosed Stage III-IV ovarian carcinoma with bulky residual disease or with recurrent ovarian carcinoma regardless of the interval since the last chemotherapy is chemotherapy plus angiogenesis inhibitor followed by maintenance with an angiogenesis inhibitor.Pro: James Tate Thigpen, MDCon: Michael J. Birrer, MD, PhD
9:10 am Expert Debate #3: Patients with locally advanced (Stage III-IVA) endometrial carcinoma should undergo surgical resection followed by chemotherapy plus volume-directed radiation.Pro: Robert Allen Burger, MD, FACOG, FACSCon: James Tate Thigpen, MD
9:40 am Break
10:10 am Expert Debate #4: Patients with recurrent cervical carcinoma metastatic to sites outside of the pelvis should be treated with a combination of chemotherapy plus angiogenesis inhibitor.Pro: Mark A. Morgan, MD, FACOG, FACSCon: Maurie Markman, MD
10:40 am Expert Debate #5: Patients with metastatic carcinosarcoma of the uterus should be treated with a combination of ifosfamide plus paclitaxel.Pro: James Tate Thigpen, MD Con: Robert Allen Burger, MD, FACOG, FACS
11:10 am Tumor Board Discussing Cases Submitted by Audience in Advance of Conference (includes working lunch)
Afternoon Session
12:50 pm Emerging Therapies: Angiogenesis Inhibitors Robert Allen Burger, MD, FACOG, FACS
1:15 pm Emerging Therapies: PARP InhibitorsMichael J. Birrer, MD, PhD
1:40 pm Other Novel Targets and New Therapeutic Agents Russell J. Schilder, MD
2:05 pm Break
2:35 pm Update on Robotic SurgeryMark A. Morgan, MD, FACOG, FACS
3:00 pm Expert Debate #6: Genomic analysis is critical for the proper management of gynecologic cancer patients.Pro: Michael J. Birrer, MD, PhDCon: Maurie Markman, MD
3:35 pm Summary of the Day and ConclusionsMichael J. Birrer, MD, PhD
3:45 pm Adjourn
Lectures include a 5-minute Q&A session
James Tate Thigpen, MDProfessor of MedicineDirector, Division of Medical OncologyUniversity of Mississippi School of MedicineJackson, Mississippi Maurie Markman, MDSenior Vice President of Clinical Affairs &
National Director, Medical OncologyCancer Treatment Centers of AmericaPhiladelphia, Pennsylvania
Michael J. Birrer, MD, PhDProfessor, Department of MedicineHarvard Medical SchoolDirector of Gynecologic Medical OncologyMassachusetts General HospitalBoston, Massachusetts
Robert A. Burger, MD, FACOG, FACSProfessor, Department of Surgical OncologyDirector, Women’s Cancer CenterFox Chase Cancer CenterPhiladelphia, Pennsylvania
Mark A. Morgan, MD, FACOG, FACSPhiladelphia, Pennsylvania
Russell J. Schilder, MDProfessor of Medical Oncology and GynecologyJefferson Medical College of Thomas Jefferson University
Director, Gynecologic Medical OncologyKimmel Cancer Center at JeffersonPhiladelphia, Pennsylvania
Ovarian CancerAND GYNECOLOGIC MALIGNANCIES®
INTERNATIONAL SYMPOSIUM ON9th
Annual
OVERVIEW AND PURPOSEThe 9th Annual International Symposium on Ovarian Cancer and Gynecologic Malignancies® is a one-day educational and scientific meeting that will focus on key clinical topics in the management of ovarian cancer as well as endometrial, uterine, and cervical malignancies. Join our faculty of national experts as they debate and discuss the individualization of treatment plans for patients with gynecologic cancers (such as surgery, adjuvant therapy, chemotherapy, and maintenance therapy), as well as the role of robotic surgery and genomic analyses. Promising novel chemotherapeutics and targeted agents for gynecologic malignancies currently undergoing clinical trial evaluation will also be highlighted during the program. Finally, participants will have an opportunity to submit their own cases for discussion with a faculty tumor board.
TARGET AUDIENCEThis educational activity is directed toward medical oncologists and fellows who treat patients with ovarian cancer. Gynecologic oncologists, surgical oncologists, radiation oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of ovarian cancer will be invited to participate.
LEARNING OBJECTIVES• Formulate frontline and subsequent therapy for patients based upon patient/disease
characteristics including use of surgery and adjuvant therapy• Discuss the use of first-line intraperitoneal chemotherapy for eligible patients with ovarian cancer• Describe the value of maintenance therapy for appropriate patients with ovarian cancer
following first-line chemotherapy• Assess treatment options for second-line therapy for recurrent metastatic ovarian cancer based
on sensitivity or resistance to prior platinum-based chemotherapy• Evaluate data on new agents and approaches in development for ovarian cancer• Recommend appropriate patients with ovarian cancer for clinical trial enrollment
ACCREDITATION/DESIGNATION OF CREDITPhysicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.